Discriminant Analysis of Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide, and C-Reactive Protein for Rheumatoid Arthritis Patients
Keywords:
Rheumatoid arthritis, discriminant analysis, C-Reactive Protein, ArthritisAbstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality with uncertain aetiology by significant morbidity and mortality. Prevalence of approximately 0.75% in India. About 40% diseased become work disabled within 5 years from onset of symptoms.
Objectives: The study was conducted to determine the most parsimonious way to distinguish between groups and to test the theory by which cases are classified as predicted.
Method: The study is based on 290 clinically suspected RA patients. Cross-sectional study design was used. Clinically suspected cases were referred by different OPD’s of Sir Sunderlal Hospital for screening.
Result: RF, AntiCCP and CRP diagnosed RA 21.3%, 21.7% and 33.1% respectively as positive . 277/290 (92.1%) of respondents were classified correctly into ‘RA’ or ‘non-RA’ groups. Non-RA were classified with better accuracy (98.8%) than RA (58.3%).
Interpretation & Conclusion: Early diagnosis of these high risk suspects will help in preventing from foremost disability. The quality of life may be approved of infected subjects by providing timely diagnosis and treatments and balanced nutritional and social supports.
References
Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1:1108–11.
Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheu-matoid arthritis. Arthritis Rheum 1986;29:706–14.
Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864–72.
Isomaki H. Long-term outcome of rheumatoid arthritis. Scand J Rheumatol Suppl 1992;95:3–8.
Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl. 1996;44:13–22.
O’Dell JR. Rheumatoid arthritis: the clinical picture. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Con-ditions. A Textbook of Rheumatology. Lippincott Williams & Wilkins, Baltimore, MA.2005; 1165– 94.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid ar-thritis. Arthritis Rheum 1988;31:315-24.
Rose HM, Ragan C, Pearce E, Lipman MO. Differential ag-glutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1949;68:1–6.
Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47.2001; 1089–93.
Schellekens GA, Visser H, de jong BA, et al. The diagnostic properties of RA antibodies to cyclic citrullinated peptide. Arthritis Rheum 43.2000; 155–63.
Schellekens GA, de jong BA, van den Hoogen FH, et al. Cit-rullin is an essential constituent of antigenic determinants recognized by RA, specific autoantibodies. J Clin Invest 1998; 101: 273–8.
Nienhuis RLF, Mandema E. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964;23:302-5.
Schellekens GA, Visser H, de jong BA, et al. The diagnostic properties of RA antibodies to cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155–63.
Steuer A, Watkins J, Smith F, Day L, Demetriadi F, Chapel H, RF latex and anti-CCPantibodies: a combined strategy for diagnosing RA in primary? Rheumatology.2008; 47:375-376.
Gupta R, Thabah MM, Aneja R, Kumar A, Varghese T, Chandrasenan PJ. Usefulness of anti-CCP antibodies in rheumatic disease in India patients. Indian J Med Sci. 2009; 63:92-100.
Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting pro-gression of palindromic rheumatism to rheumatoid arthri-tis. J Rheumatol 2006; 33:1240-2.
Vincent C, de Keyser F, Masson-Bessie`re C, Sebbag M,Veys EM, Serre G. Anti-perinuclear factor compared with the so called “antikeratin” antibodies and antibodies to human ep-idermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis 1999; 58:42-8.
van der Helm-van Mil AH. Antibodies to citrullinated pro-teins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7:949-58.
Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoan-tibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2:236-43.
Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Di-agnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47:1089-93.
Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357-65.
Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62:870-4.
Aho K, Heliovaara M, Maatela J, Tuomi T, Palusuo T. Rheuma-btoid factors antedating clinical rheumatoid arthri-tis. J Rheumatolb1991; 18:1282–4.
Aho K, von Essen R, Kurki P, Palusuo T, Heliovaara M. Antik-beratin antibody and antiperinuclear factor as mark-ers for subclin-ical rheumatoid disease process. J Rheu-matol 1993; 20:1278–81.
Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ,bvan der Horst-Bruinsma IE, de Koning MM, et al. Specificbautoantibodies precede the symptoms of rheuma-toid arthritis: a study of serial measurements in blood do-nors. Arthritis Rheum v.2004; 50:380–6.
Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G,Wadell G, Stenlund H, et al. Antibodies against cyclic cit-rullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741–9.
Soothill, J F, Lectures on the Scientific Basic of Medicine,. London, Athlone Press, 1967; 276.
Aronsen, K F, et al, Scandinavian Journal of Clinical and Laboratory Investigation, suppl No 124.1972; 20:124.
Koj, A, in Structure and Function of Plasma Proteins, vol 1, ed A C Allison, London and New York, Plenum Press, 1974; 73.
Hardwicke, J, and Squire, J R, Clinical Science, 1952; 2:333
Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheuma-toid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 1979; 66:377-84.
Young A, Corbett M, Winfield J et al. A prognostic index for erosive changes in the hands, feet, and cervical spine in ear-ly rheumatoid arthritis. Br J Rheumatol 1988; 27:94-101.
Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de Putte LBA. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the litera-ture. Semin Arthritis Rheum 1988; 17:284-92.
Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de Putte LBA. prognostic factors for radiographic dam-age and physical disability in early rheumatoid arthritis. aprospective follow-up study of 147 patients. British Jour-nal of Rheumatology 1992; 31:519-525.
Robert PB, Richard B.Business Research Methods and Sta-tistics Using SPSS. SAGE Publications Ltd. 2009; 560.
Hui Bian. Office for Faculty Excellence. Available at <https://www.coursehero.com/file/14243198/DiscriminantAnalysisppt/>. Accessed January 10th , 2016
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
